Shares of American Renal Associates Holdings Inc. (NYSE:ARA) traded up 5.5% on Monday . The stock traded as high as $27.49 and last traded at $27.10, with a volume of 83,622 shares changing hands. The stock had previously closed at $25.68.

Several analysts have weighed in on the company. Leerink Swann reissued an “outperform” rating on shares of American Renal Associates Holdings in a report on Monday, May 16th. Goldman Sachs Group Inc. assumed coverage on American Renal Associates Holdings in a report on Monday, May 16th. They issued a “neutral” rating and a $30.00 target price on the stock. Wells Fargo & Co. assumed coverage on American Renal Associates Holdings in a report on Monday, May 16th. They issued an “outperform” rating on the stock. SunTrust Banks Inc. started coverage on American Renal Associates Holdings in a report on Monday, May 16th. They issued a “buy” rating and a $34.00 target price on the stock. Finally, Barclays PLC started coverage on American Renal Associates Holdings in a research note on Monday, May 16th. They set an “overweight” rating and a $33.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $32.50.

The company’s 50 day moving average price is $0.00 and its 200-day moving average price is $0.00. The company has a market cap of $608.36 million and a price-to-earnings ratio of 13.95.

American Renal Associates Holdings (NYSE:ARA) last announced its earnings results on Thursday, May 12th. The company reported $0.16 earnings per share for the quarter. The business had revenue of $172.10 million for the quarter, compared to the consensus estimate of $149.30 million. On average, equities research analysts expect that American Renal Associates Holdings Inc. will post $0.88 EPS for the current year.

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.